Novo Nordisk raises guidance as oral GLP-1 launch gains ground
Barron's frames the guidance increase around Novo's position in the oral incretin race against Eli Lilly's orforglipron.
The wire
- 01Novo Nordisk raised its guidance, with Barron's tying the move to early performance of its oral GLP-1 against Lilly's competing pill.
- 02Oral incretin uptake shapes supply planning and payer negotiations for pharmacies and telehealth operators fielding pill-versus-injection requests.
- 03Detailed launch figures and the durability of Novo's oral lead remain to be confirmed in subsequent reporting.
From the source
Read at barrons.comNovo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance.